Key Developments For Cardiac Science Corporation
Cardiac Science Corporation (CSCX.O) (Consolidated Issue listed on NASDAQ Global Market)
Cardiac Science Corp Issues Q4 2009 Guidance; Earnings Guidance Below Analysts' Estimates
Cardiac Science Corp announced that for the fourth quarter of 2009, it expects revenue to be in a range between $39.0 million and $41.0 million and net loss in a range between $4.0 and $5.0 million, or between $0.17 and $0.21 per share. According to Reuters Estimates, analysts were expecting the Company to report revenue of $40.0 million, net profit of $(1.0) million and earnings of $(0.05) for the same period.
Cardiac Science Corp Issues Q3 2009 Guidance; Revenue Guidance In Line With Analysts' Estimates
Cardiac Science Corp announced that for third quarter of 2009, it expects revenue to be in the range of $37-$40 million and net loss to be in the range of $0.10-$0.14 per share, excluding expenses relating to a possible field action. According to Reuters Estimates, analysts were expecting the Company to report revenue of $40 million for the same period.
Cardiac Science Corp Issues Q2 2009 Guidance Below Analysts' Estimates-Conference Call
Cardiac Science Corp announced that for the second quarter of 2009 it expects revenue to be in a range between $37 and $39 million and GAAP net loss in a range between $0.03 and $0.05 per share. According to Reuters Estimates, analysts on an average were expecting the Company to report earnings per share (EPS) of $0.02 on revenue of $40 million for the same period.
Cardiac Science Corp Issues Q1 2009 Guidance Below Analysts' Estimates
Cardiac Science Corp announced that for first quarter of 2009, it expects revenue to be in the range of $39-$40 million and net income to be positive, with fully diluted earnings per share (EPS) to be in the range around $0.01. According to Reuters Estimates, analysts were expecting the Company to report revenue of $50 million and EPS of $0.05 for the same period.
Cardiac Science Corp Announces Changes In Management
Cardiac Science Corp announced the appointment of Dave Marver as the Company's new President and Chief Executive Officer(CEO). Mr. Marver, currently serves as the Company's Chief Operating Officer and succeeds the Company's current CEO, John Hinson, who is leaving the Company for personal reasons, effective March 30, 2009. Mr. Marver will become CEO and replace Mr. Hinson on the Board of Directors, effective March 31, 2009
